Search Results

• • 341 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma

  Authors:Carmelo Carlo-Stella and Armando SantoroFrom:Biomarkers in Medicine (Vol. 9, Issue 8) Peer-Reviewed

  Aug. 20158,693 words Report 2110LAuthor(s): Carmelo Carlo-Stella [*] aff1 aff2 , Armando Santoro aff1 Keywords: brentuximab vedotin; CD30; classical Hodgkin's lymphoma; Hodgkin Reed-Sternberg cells; nivolumab; PD-1 ligands; PD-1 receptor;...

• Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma

  Authors:H. Degroote, A. Van Dierendonck, A. Geerts, H. Van Vlierberghe, and L. DevisscherFrom:Journal of Immunology Research (Vol. 2018) Peer-Reviewed

  Annual 20185,543 words Article 1480LHepatocellular carcinoma (HCC) most often develops in patients with underlying liver disease characterized by chronic nonresolving inflammation. Tumor-associated macrophages (TAMs) are one of the most abundant immune...

• Current Diagnosis and Management of Small-Cell Lung Cancer

  Authors:Shuhang Wang, Stefan Zimmermann, Kaushal Parikh, Aaron S. Mansfield, and Alex A. AdjeiFrom:Mayo Clinic Proceedings (Vol. 94, Issue 8) Peer-Reviewed

  Aug. 201911,025 words Article 1660LAbstract Small-cell lung cancer (SCLC) is an aggressive disease with distinct pathological, clinical, and molecular characteristics from non--small-cell lung cancer. SCLC has high metastatic potential, resulting in a...

• Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.

  Authors:Miyuki Sato, Satoshi Watanabe, Hiroshi Tanaka, Koichiro Nozaki, Masashi Arita, Miho Takahashi, et al.From:PLoS ONE (Vol. 14, Issue 4) Peer-Reviewed

  Apr. 12, 20194,575 words Report 1520LAlthough the blockade of programmed cell death 1 (PD-1)/PD-ligand (L) 1 has demonstrated promising and durable clinical responses for non-small-cell lung cancers (NSCLCs), NSCLC patients with epidermal growth factor...

• Appendix 1: Summary of clinical evidences in oral cavity, oropharyngeal, laryngeal and hypopharyngeal cancers.

  Author:.From:Indian Journal of Cancer (Vol. 57, Issue 5) Peer-Reviewed

  Feb. 2020544 words Clinical report Byline: .. References 1. Kumar A, Sharma A, Mohanti BK, Thakar A, Shukla NK, Thulkar SP, et al. Aphase 2 randomized study to compare short course palliative radiotherapy with short course concurrent palliative...

• The Cancer Immunotherapy Biomarker Testing Landscape.

  Authors:Eric E. Walk, Sophia L. Yohe, Amy Beckman, Andrew Schade, Mary M. Zutter, John Pfeifer, et al.From:Archives of Pathology & Laboratory Medicine (Vol. 144, Issue 6) Peer-Reviewed

  June 202014,425 words Article 2040L* Context.--Cancer immunotherapy provides unprecedented rates of durable clinical benefit to late-stage cancer patients across many tumor types, but there remains a critical need for biomarkers to accurately predict...

• Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting.

  Authors:Jing-Zhou Hou, Jing Christine Ye, Jeffrey J. Pu, Hongtao Liu, Wei Ding, Hong Zheng, et al.From:Journal of Hematology & Oncology (Vol. 14, Issue 1) Peer-Reviewed

  Apr. 21, 202118,348 words Article 1360LAntibodies and chimeric antigen receptor-engineered T cells (CAR-T) are increasingly used for cancer immunotherapy. Small molecule inhibitors targeting cellular oncoproteins and enzymes such as BCR-ABL, JAK2, Bruton...

• Transdiaphragmatic nephrectomy with synchronous pulmonary and anterior thoracic wall mass metastasectomy in a young male with metastatic renal cell carcinoma; a single-incision approach.

  Authors:Lazaros Lazarou, Marinos Berdempes, Angeliki Peninta, Maria Mitselou, Andreas Skolarikos, and Achilleas LiouliasFrom:Urology Annals (Vol. 13, Issue 2) Peer-Reviewed

  April-June 20211,787 words Article 1580LByline: Lazaros. Lazarou, Marinos. Berdempes, Angeliki. Peninta, Maria. Mitselou, Andreas. Skolarikos, Achilleas. Lioulias Renal cell carcinoma represents approximately 3% of all cancers, with the highest incidence...

• Pivotal PD-1 Treatment Helps Change Standard of Care in Lung Cancer: "Having the opportunity to work within the industry in that sort of capacity, and then seeing a drug translate into clinical benefit in the clinic, was very exciting and gratifying".

  Author:Julie R. BrahmerFrom:Oncology (Vol. 35, Issue 12) Peer-Reviewed

  Dec. 20212,062 words Interview 1370LSince the first information regarding single-agent PD-1 inhibitors were presented at the American Society of Clinical Oncology Annual Conference a decade ago, immune checkpoint inhibitors (ICIs) have been widely used in...

• The Relationship Between Checkpoint Inhibitors and the Gut Microbiome and Its Application in Prostate Cancer.

  Authors:Ashray Maniar, Amy E. Moran, and Julie N. GraffFrom:Oncology (Vol. 34, Issue 3) Peer-Reviewed

  Mar. 20204,144 words Article 2010LIndications for checkpoint inhibitors (CPIs) are growing rapidly within the field of oncology; however, they continue to have heterogeneous outcomes in different cancers. Other than mismatch repair deficiency, there are...

• Expression of programmed death-ligand 1 in cutaneous squamous cell carcinoma arising in sun-exposed and nonsun-exposed skin.

  Authors:Hiroyuki Goto, Kazunari Sugita, and Osamu YamamotoFrom:Indian Journal of Dermatology (Vol. 65, Issue 6) Peer-Reviewed

  Nov-Dec 20201,816 words Article 1790LByline: Hiroyuki. Goto, Kazunari. Sugita, Osamu. Yamamoto Background: A recent clinical trial has shown the efficacy of an anti-programmed death-1 (PD-1) antibody against advanced squamous cell carcinoma (SCC). The...

• Identification of a Ten-Gene Signature of DNA Damage Response Pathways with Prognostic Value in Esophageal Squamous Cell Carcinoma.

  Authors:Weitao Zhuang, Xiaosong Ben, Zihao Zhou, Yu Ding, Yong Tang, Shujie Huang, et al.From:Journal of Oncology (Vol. 2021) Peer-Reviewed

  Dec. 22, 20216,115 words Article 1500LMolecular prognostic signatures are critical for treatment decision-making in esophageal squamous cell cancer (ESCC), but the robustness of these signatures is limited. The aberrant DNA damage response (DDR) pathway may...

• Exploring Emerging Immunotherapies in Melanoma.

  From:Oncology (Vol. 35, Issue 11) Peer-Reviewed

  Nov. 20212,892 words Article 1700LLEARNING OBJECTIVES Upon successful completion of this activity, you should be better prepared to: * Describe the mechanism of actions of novel immune checkpoint inhibitors for the treatment of cancer * Explain the...

• Immune checkpoint inhibitors (Nivolumab)-induced enterocolitis demonstrated on 18Fluorine-fluorodeoxyglucose positron emission tomography-computed tomography

  Authors:Sharjeel Usmani, Rashid Rasheed, Fahad Marafi, and Fareeda Al KandariFrom:Indian Journal of Nuclear Medicine (Vol. 34, Issue 2) Peer-Reviewed

  April-June 2019875 words Article 1710LByline: Sharjeel. Usmani, Rashid. Rasheed, Fahad. Marafi, Fareeda. Al Kandari Nivolumab, an immune checkpoint inhibitor, is a humanized anti-programmed death-1 monoclonal antibody that is used for the treatment of...

• Roche splashes $2.4 billion on Foundation Medicine's cancer platform.

  Author:Cormac SheridanFrom:Nature Biotechnology (Vol. 36, Issue 9) Peer-Reviewed

  Oct. 20181,878 words Article 1420LAuthor(s): Cormac Sheridan 1 Author Affiliations: (1) Dublin, Roche has redoubled its commitment to precision oncology by taking full ownership of Foundation Medicine, a pioneer of genomic tumor profiling, in a...

• Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries.

  Authors:Biancamaria Cembrola, Valentino Ruzza, Fulvia Troise, Maria Luisa Esposito, Emanuele Sasso, Valeria Cafaro, et al.From:BioMed Research International (Vol. 2020) Peer-Reviewed

  Jan. 202013,418 words Article 1670LThe affinity engineering is a key step to increase the efficacy of therapeutic monoclonal antibodies and yeast surface display is the most widely used and powerful affinity maturation approach, achieving picomolar...

• Time to dissect the autoimmune etiology of cancer antibody immunotherapy.

  Authors:Michael Dougan and Massimo PietropaoloFrom:Journal of Clinical Investigation (Vol. 130, Issue 1) Peer-Reviewed

  Jan. 20208,857 words Article 1430LImmunotherapy has transformed the treatment landscape for a wide range of human cancers. Immune checkpoint inhibitors (ICIs), monoclonal antibodies that block the immune-regulatory "checkpoint" receptors CTLA-4, PD-1, or...

• Visceral leishmaniasis in a 62-year-old woman with metastatic renal cancer in treatment with nivolumab.

  Authors:Kevin Doello, VíCtor Amezcua, Alicia Delgado, and Javier ValdiviaFrom:Indian Journal of Medical and Paediatric Oncology (Vol. 41, Issue 2) Peer-Reviewed

  April-June 2020767 words Letter to the editor 1310LByline: Kevin. Doello, Víctor. Amezcua, Alicia. Delgado, Javier. Valdivia Visceral leishmaniasis is a parasitic disease typical of tropical and Mediterranean regions. In Spain, it is caused by Leishmania infantum . In...

• Emerging therapeutic agents for advanced non-small cell lung cancer.

  Authors:Ruqin Chen, Rami Manochakian, Lauren James, Abdel-Ghani Azzouqa, Huashan Shi, Yan Zhang, et al.From:Journal of Hematology & Oncology (Vol. 13, Issue 1) Peer-Reviewed

  May 24, 202015,333 words Article 1200LAdvanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a poor prognosis and no known cure. Survival time is often short because of limited treatment options. Recent advances in targeted...

• Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy

  Authors:Maria Giuseppa Vitale, Sarah Scagliarini, Luca Galli, Sandro Pignata, Giovanni Lo Re, Alfredo Berruti, et al.From:PLoS ONE (Vol. 13, Issue 7) Peer-Reviewed

  July 6, 20183,767 words Report 1560LBackground Results from phase III clinical trial CheckMate 025 have established nivolumab as the standard of care for treatment of metastatic renal-cell carcinoma (mRCC) after VEGF inhibitor failure; however, elderly...